We extend our full-spectrum Pharmaceutical Development & Manufacturing expertise to the rapidly evolving field of bispecific antibodies. Building on deep capabilities in Drug Substance Development and Monoclonal Antibody Development, we deliver seamless, science-driven programs that translate dual-target concepts into drug substances within accelerated timelines.
Overview of Bispecific Antibody Development
Bispecific antibodies (bsAbs) unite two independent antigen-binding sites in a single molecular architecture, enabling concurrent engagement of distinct targets or cell types. This synergy unlocks modalities such as immune-cell redirection, receptor cross-linking, and dual-pathway blockade while potentially lowering dose burden and resistance risk. Yet, the structural diversity of bsAb formats—from knob-into-hole IgGs to asymmetric T-cell engagers—introduces challenges in chain pairing, manufacturability, developability, and analytics. We mitigate these complexities through platformable process designs, modular assay panels, and predictive in-silico assessments that de-risk progression from laboratory concept to cGMP supply.
Our Bispecific Antibody Development Services
Our integrated bispecific antibodies development service includes high-productivity CHO cell line engineering, design of experiment (DoE)-driven upstream optimization, cGMP-scalable purification, ICH-aligned analytical characterization, and formulation-stability engineering for high-concentration delivery.
Cell Line Engineering Service
We generate high-productivity, genetically stable CHO cell pools and clones capable of coordinated expression of disparate heavy and light chains. Using proprietary signal peptide libraries and dual-promoter vectors, we optimize chain-ratio stoichiometry and mitigate mispairing. Early developability screens—including differential scanning fluorimetry and transient aggregation stress tests—prioritize constructs with robust manufacturability before clone selection.
Upstream Process Development Service
Our scientists design fed-batch and perfusion strategies that accommodate the elevated metabolic demand of bsAb assembly. Through DoE matrices, we interrogate variables such as amino-acid feed gradients, redox potential, and culture osmolality to enhance correct heterodimer formation and titre. Scale-down bioreactor models (3 L–15 L) emulate commercial-scale shear and mass-transfer profiles, ensuring translatability to 750 L single-use or stainless-steel platforms.
Downstream Purification Service
We deploy orthogonal chromatography schemes—Protein A capture with pH-selective elution, followed by differential cation-exchange or mixed-mode polishing—to resolve product-related impurities, half-antibodies, and high-molecular-weight species. Continuous processing options such as periodic counter-current chromatography are available to maximize yield and buffer economy. All methods are established under scalable, cGMP-compliant protocols and transferred seamlessly to manufacturing suites.
Analytical Characterization Service
Comprehensive structural and functional confirmation is performed under ICH-Q6B and USP guidelines. High-resolution native MS and subunit mapping verify correct chain pairing, while multi-attribute LC–MS workflows quantify critical quality attributes in a single run. Functional potency is assessed through reporter-gene assays and target-bridging surface-plasmon resonance, delivering mode-of-action–relevant release specifications.
Stability Service
In parallel with upstream activities, we conduct accelerated and real-time stability studies across pH, ionic strength, and excipient landscapes to define a formulation that preserves epitope accessibility and minimizes liquid-phase aggregation.
We integrate state-of-the-art cell line, process, and analytical services into a single, agile CDMO framework that shortens development pathways for bispecific antibodies. Partner with us to transform innovative dual-target concepts into high-quality pharmaceutical materials with confidence and speed.
Frequently Asked Questions
Q1: How do you address mispairing during bispecific antibody expression?
We employ optimized vector architectures, adjust chain-ratio gene copy numbers, and implement selective media pressure to favor correctly paired heterodimers. Post-expression, our purification cascade efficiently removes residual mispaired species, ensuring product consistency.
Q2: Can you support non-IgG bsAb formats such as tandem scFvs?
Yes. Our modular workflow accommodates IgG-like, tandem scFv, and Fab-scFv fusions. Upstream media supplements and downstream hydrophobic-interaction steps are tailored for smaller, high-surface-area constructs without compromising scalability.
Q3: Do you provide fill-finish for bispecific antibodies?
Absolutely. Although our primary focus is drug-substance R&D, our integrated network offers aseptic vial and pre-filled syringe filling isolator technology, streamlining the path to distribution.
Our products and services are for research use only.
